Coherus Oncology (CHRS) Leases (2019 - 2025)
Coherus Oncology (CHRS) has disclosed Leases for 8 consecutive years, with $3.0 million as the latest value for Q4 2025.
- Quarterly Leases fell 34.64% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 34.64% year-over-year, with the annual reading at $3.0 million for FY2025, 34.64% down from the prior year.
- Leases hit $3.0 million in Q4 2025 for Coherus Oncology, down from $4.5 million in the prior quarter.
- In the past five years, Leases ranged from a high of $9.4 million in Q1 2021 to a low of $3.0 million in Q4 2025.
- Historically, Leases has averaged $6.1 million across 5 years, with a median of $5.8 million in 2022.
- Biggest five-year swings in Leases: skyrocketed 464.65% in 2021 and later crashed 34.64% in 2025.
- Year by year, Leases stood at $8.2 million in 2021, then tumbled by 30.55% to $5.7 million in 2022, then grew by 3.9% to $5.9 million in 2023, then dropped by 23.58% to $4.5 million in 2024, then plummeted by 34.64% to $3.0 million in 2025.
- Business Quant data shows Leases for CHRS at $3.0 million in Q4 2025, $4.5 million in Q4 2024, and $5.9 million in Q4 2023.